COMPLEMENT FACTOR H Y403H POLYMORPHISM IN THE TURKISH POPULATION
Yunus Arikan Y, Türker Bilgen T, Ibrahim Keser I,
*Corresponding Author: Ibrahim Keser, Department of Medical Biology and Genetics, Faculty of Medicine, Akdeniz University, TR-07059, Antalya, Turkey; Tel.:+90-242-249-6973; Fax:+90- 242-227-4495; E-mail: keser@akdeniz.edu.tr
page: 41

DISCUSSION

The CFH-mediated inactivation of the alternative pathway protects the host cell membranes from excessive complement system activation. The Y402H substitution interferes with the binding ability of the SCR7 domain for poly-anionic molecules such as heparin and CRP, which are biological markers of inflammation [6,20]. As a consequence, this variant leads to cell loss and increased damage of target tissues. The CFH mutations and variants have been associated with renal and ocular conditions like MPGN2, aHUS, basal laminar drusen, and AMD. Sometimes patients may have more than one of these conditions, suggesting common mechanisms in their pathogenesis [1]. However, there is no straightforward genotype-phenotype correlation between the CFH variants and disease [1]. It has been reported that the C allele for the CFH c.1277 T>C polymorphism increases the odds ratio of AMD up to 6-fold in different populations except the Japanese [21-23]. An 8-fold increased risk of developing AMD has been reported for the CC genotype with a positive family history of AMD [16]. Ethnic differences in disease-susceptible genomic alterations have also been shown for the CFH-related phenotypes [24,25]. While the C allele frequency varies between 0.30 and 0.39% in different Caucasian populations, its frequency is 0.11% for Japanese people [24,29]. We found the C allele frequency to be 0.35% in our Turkish population (Table 1). This C allele frequency makes it important, especially for AMD in Turkey. Our experimental results revealed no other SNPs in the region comprising the SCR-7 domain of the CFH gene. This may imply that the SCR-7 domain is a conserved and func-tionally-important region of the CFH gene.



Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006